Clinical trials
Colorectal Cancer Recurrent clinical trials
Below are recruiting colorectal cancer recurrent clinical trials, each written for real people, not researchers. We’re tracking 230 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07268846Recruiting
Prebiotic supplement before colorectal cancer surgery
This trial tests if taking a postbiotic supplement before surgery for colorectal cancer can improve recovery. It may help patients with adenocarcinoma of the large intestine prepare for their operation.
São Paulo, São PauloAges 18 years+ - NCT06821048RecruitingPhase 1
CAR-T cells targeting CEA for advanced solid tumors
This trial tests a new treatment called CAR-T cells that are designed to attack cancer cells positive for CEA protein. It's for people with advanced solid tumors like colorectal or lung cancer who have run out of standard options.
Hangzhou, ZhejiangAges 18 years+ - NCT07578571RecruitingPhase 1
Testing a New Cancer Treatment Called IM-1617
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
Sarasota, FloridaAges 18 years+ - NCT06271941Recruiting
Reducing polyp return after large colon polyp removal
This trial is testing a standard way to remove large polyps from the colon and checking if it helps prevent them from coming back. It's for people who have a large non-cancerous polyp that needs to be taken out during a colonoscopy.
Montreal, QuebecAges 18 years+ - NCT04930432RecruitingPhase 1/Phase 2
MCLA-129 for advanced EGFR- and MET-positive lung and other cancers
This early-phase trial tests MCLA-129, an antibody that targets EGFR and MET, in people with advanced cancers that have specific lab “biomarker” results. It’s for patients whose cancer has grown after standard treatments or can’t take standard treatment, with the goal of shrinking tumors and improving symptoms.
BaodingAges 18 years+ - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Scottsdale, ArizonaAges 18 years+ - NCT06682793RecruitingPhase 1/Phase 2
Study of A2B395 therapy for solid tumors with EGFR and HLA loss
This trial tests a new cell therapy called A2B395 for cancers that have EGFR, a protein on the cell surface, and have lost a specific marker called HLA-A*02. The therapy uses specially engineered immune cells to target and kill these cancer cells. This may help patients with colorectal, lung, head and neck, breast, kidney, or other solid tumors that are no longer responding to standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT05746897RecruitingPhase 1
First-in-human test of an anti-PVRIG drug for advanced cancers
This early-phase study tests NM1F (an anti-PVRIG antibody) in people with advanced solid tumors to see if it’s safe and whether it may work. It also includes pembrolizumab (a PD-1 “checkpoint” medicine), aiming to boost the immune system against the cancer.
Dallas, TexasAges 18 years+ - NCT06265025RecruitingPhase 1/Phase 2
GM103 injection for advanced solid tumors that can't be removed
This trial tests an experimental drug called GM103 that is injected directly into tumors. It is for people with advanced solid tumors that have not responded to other treatments and cannot be surgically removed.
Goyang-si, Gyeonggi-doAges 18 years+ - NCT05985954RecruitingPhase 1
Ulixertinib with cetuximab for colorectal cancer
This trial tests whether the drug ulixertinib, combined with cetuximab (and sometimes encorafenib), can help people with advanced or metastatic colorectal cancer who have already tried EGFR or BRAF-targeted therapy. It aims to find new treatment options for these patients.
Houston, TexasAges 18 years+ - NCT03659448RecruitingPhase 3
Test drug that helps map colon and rectal cancer during surgery
This Phase 3 study tests SGM-101, a drug used during surgery to help doctors better outline primary, recurrent, and spread (metastatic) colorectal cancer. It may improve how completely tumors are identified and removed during an operation.
Duarte, CaliforniaAges 18 years+ - NCT06589440RecruitingPhase 2
Study of SR-8541A plus two immunotherapies for advanced colorectal cancer
This trial tests a new drug combination (SR-8541A, botensilimab, and balstilimab) for people with a specific type of metastatic colorectal cancer that is not MSI-high. It aims to see if this combination can help when other treatments have stopped working.
Morristown, New JerseyAges 18 years+ - NCT07189871RecruitingPhase 1/Phase 2
177Lu-BetaBart for advanced solid tumors
This trial tests a new radioactive drug, 177Lu-BetaBart, for people with certain advanced solid tumors that have stopped responding to other treatments. The goal is to see if it can shrink tumors or slow their growth.
Dothan, AlabamaAges 18 years+ - NCT05806931RecruitingPhase 2
Alternating two pills plus bevacizumab for advanced colon cancer
This Phase 2 study tests a treatment plan that alternates two cancer pills and adds bevacizumab (a blood-vessel drug) for metastatic colon cancer that has come back or worsened after standard treatment. It may help shrink tumors and slow disease growth after later-line therapy options.
Elizabeth, New JerseyAges 18 years+ - NCT06848842RecruitingPhase 2
Ivonescimab and chemotherapy for colorectal cancer that spread only to the liver
This trial tests a new drug called ivonescimab combined with chemotherapy for people whose colorectal cancer has spread only to the liver and cannot be surgically removed right away. The goal is to see if this combination can shrink the tumors enough to allow surgery or other treatments.
BeijingAges 18 years+ - NCT07085091RecruitingPhase 1
Study of ALX2004 for advanced solid tumors
This trial tests a new drug, ALX2004, for people with certain advanced cancers (head and neck, lung, esophagus, or colorectal) that have stopped responding to standard treatments. The goal is to see if the drug is safe and effective.
Tampa, FloridaAges 18 years+ - NCT06130826RecruitingPhase 1
Immune therapy and radiation for advanced colorectal or breast cancer
This trial tests a combination of stereotactic body radiation therapy (SBRT) and an immune-boosting drug (M5A-IL2) for colorectal or breast cancer that has spread and is no longer responding to standard treatments. The goal is to activate your immune system to fight the cancer.
Duarte, CaliforniaAges 18 years+ - NCT07106034RecruitingPhase 2
Testing a new combo therapy for advanced colorectal cancer
This trial tests a combination of two drugs (ONGERICIMAB and TORIPALIMAB) for people with a specific type of colorectal cancer that did not respond to first treatment. It aims to see if this new approach can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06958419RecruitingPhase 2/Phase 3
Short radiation plus targeted drugs for advanced colon cancer
This trial tests a combination of short-course radiation, chemotherapy, targeted therapy (bevacizumab), and an immunotherapy drug (PD-1 inhibitor) for people with advanced colorectal cancer that has spread and is not curable with surgery. It aims to see if this approach can help shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06154538RecruitingPhase 2
Immunotherapy plus chemo vs. chemo alone for advanced colorectal cancer before surgery
This trial tests whether adding immunotherapy (a treatment that helps your immune system fight cancer) to standard chemotherapy before surgery works better than chemotherapy alone for people with locally advanced colorectal cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT05861505RecruitingPhase 3
Treatment for new liver spread from colon cancer recurrence
This Phase 3 trial studies a treatment approach for people whose colorectal cancer has come back in the liver within 12 months and can be treated with local procedures. It aims to see whether the study treatment can improve outcomes compared with standard care for people with a limited number of liver tumors.
AmsterdamAges 18 years+ - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT03526835RecruitingPhase 1/Phase 2
Study of MCLA-158 for advanced solid tumors
This trial tests a new experimental drug called MCLA-158 (petosemtamab) for people with advanced solid tumors, especially head and neck cancer or colorectal cancer, that have not responded to standard treatments. The study aims to see if this drug can shrink tumors or slow their growth.
La Jolla, CaliforniaAges 18 years+ - NCT06185556RecruitingPhase 2/Phase 3
New treatments for liver tumors near blood vessels or bile ducts
This trial tests two procedures—irreversible electroporation and stereotactic body radiotherapy—for people whose colorectal cancer has spread to the liver (1–3 tumors near major blood vessels or bile ducts) and can't be surgically removed or treated with heat. The goal is to see if these approaches can safely destroy those hard-to-reach tumors.
Amsterdam, North HollandAges 18 years+
Hear when a new Colorectal Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for colorectal cancer recurrent?
- Yes. Clin2 currently lists 230 recruiting colorectal cancer recurrent studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a colorectal cancer recurrent trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a colorectal cancer recurrent trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.